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Resumen
El cáncer de próstata es un problema 
importante para los hombres mayores en 
países desarrollados. Las decisiones acerca del 
screening y tratamiento del cáncer de próstata 
se caracterizan por múltiples opciones 
razonables que parecen “arriesgadas”, donde 
las preferencias personales de los pacientes 
son importantes. Se va reconociendo de modo 
creciente la toma de decisión compartida entre 
el paciente y el clínico como un modelo ideal 
para elecciones “sensibles a las preferencias” 
tales como las implicadas en el screening, el 
diagnóstico, y el tratamiento. Muchos ensayos 
aleatorizados de ayudas a la decisión para el 
screening de cáncer de próstata han mostrado 
consistentemente mejorías en la calidad de 
la decisión, así como un mayor interés en 
llevar a cabo la prueba del PSA cuando los 
pacientes están bien informados. En contraste, 
es necesaria una mayor investigación sobre 
el efecto de las ayudas a la decisión en las 
decisiones sobre el tratamiento del cáncer de 
próstata. Sin embargo, con los datos disponibles 
sobre su efectividad, se hace muy necesaria la 
investigación sobre el modo de implantar las 
ayudas a la decisión en el cribado con PSA, así 
como en otras decisiones críticas que se dan 
en la práctica clínica durante el tratamiento 
del cáncer de próstata. 
Palabras clave: Toma de decisión 
compartida, ayudas a la decisión, screening 
cáncer de próstata, tratamiento de cáncer de 
próstata, antígeno específi co cáncer de próstata 
(PSA). 
Abstract
Prostate cancer is an important problem 
among aging men in developed countries. 
Decisions about prostate cancer screening 
and treatment are characterized by multiple 
reasonable options and appear to be “close 
calls”, where the personal preferences of 
patients are important. Shared decision-
making between patient and clinician is 
increasingly recognized as an ideal model for 
such “preference sensitive” choices involving 
screening, diagnosis, and therapy. Many 
randomized trials of decision aids for prostate 
cancer screening have consistently shown 
improvements in decision quality as well as 
lower interest in and uptake of PSA testing when 
patients are well informed. In contrast, more 
research is needed on the effect of decision 
aids on prostate cancer treatment decisions. 
However, given the evidence of effectiveness 
available at present, research is most urgently 
needed on how to routinely implement patient 
decision aids for PSA screening, as well as 
other fateful decisions including prostate 
cancer treatment, in clinical practice.
Key words: Shared decision making, patient 
decision aids, prostate cancer screening, 
prostate cancer treatment, prostate-specifi c 
antigen.
258  Michael J. Barry
Introduction
Prostate cancer is an important health 
problem among aging men in developed 
countries worldwide. Table 1 lists prostate 
cancer incidence and mortality among a 
selected set of developed countries. The 
net benefi ts of screening and treatment 
for prostate cancer remain unclear despite 
the recent publication of several large 
randomized trials(1-3) which continue 
to engender considerable controversy. 
However, decisions about prostate cancer 
screening and treatment are characterized 
by multiple reasonable options and, based 
on these trials, do appear to be “close 
calls”, where the personal preferences 
of patients are important to making an 
optimal decision about how to proceed. 
Shared decision-making between patient 
and clinician is increasingly recognized 
as an ideal model for such “preference 
sensitive” choices involving screening, 
diagnosis, and therapy. 
Shared Decision Making
In 1997, Charles et al. clarifi ed the 
shared decision-making model for medical 
decision-making(4). They suggested the key 
characteristics of shared decision-making 
include: the involvement of at least two 
participants (usually, patient and clinician); 
both parties sharing information (usually 
the clinician information about the various 
options and possible outcomes and the 
patient about their preferences); and both 
parties work to build consensus about 
the preferred management option, and 
ultimately reach an agreement about how 
to proceed. Shared decision making has 
received considerable attention in many 
countries in recently years, including 
as a strategy for perfecting informed 
consent(5), and to help reduce unwanted 
geographic medical practice variation(6). 
This strategy might be considered an 
antidote to the problem of poor “decision 
quality;” medical decision making where 
Table 1. Prostate Cancer Incidence and Mortality in Selected Countries,
(standardized for age)(41).
Country Incidence per 100,000 Mortality per 100,000
Ireland 126.3 14.2






New Zealand 99.7 15.1
Finland 96.6 13.3
Switzerland 91.3 14.4
United States of America 83.8 9.7
Austria 83.1 12.2
Germany 82.7 11.7
The Netherlands 73.4 14.0
Denmark 72.5 19.7
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patients are uninformed and uninvolved, 
leading to decisions inconsistent with their 
preferences(7). 
A large, recent population-based 
survey of medical decision making in the 
United States covering decisions about 
cancer screening, medications for chronic 
conditions, and surgery suggested this 
type of problematic decision making is 
unfortunately too often the norm(8). For 
example, for prostate cancer screening with 
the prostate-specifi c antigen test, about 
45% of men who had faced a decision 
about testing had not been asked their 
preferences about testing, and a similar 
percentage could not correctly answer 
a single one of three basic knowledge 
questions relevant to the PSA screening 
decision(9).
Patient Decision Aids
Shared decision making may be 
facilitated by the use of patient decision 
aids. Decision aids can help clinicians 
effi ciently transfer information about 
treatment options and their outcomes to 
patients. They can also help patients clarify 
their preferences regarding the possible 
outcome states after the treatments they 
may face, particularly outcome states for 
which they have no experience as yet. 
According to the International 
and decision Aids Standards (IPDAS) 
collaboration(10), “Patient decision aids are 
tools designed to help people participate in 
decision making about health care options. 
They provide information on the options 
and help patients clarify and communicate 
the personal value they associate with 
different features of the options. 
Patient decision aids do not advise 
people to choose one option over another, 
nor are they meant to replace practitioner 
consultation. Instead, they prepare patients 
to make informed, values-based decisions 
with their practitioner.”
Numerous randomized trials of a shared 
decision making approach assisted by 
patient decision aids have been conducted 
for a plethora of management decisions. 
In a Cochrane Collaboration review of 
trials of patient decision aids updated in 
2006, 55 randomized trials of 51 different 
decision aids were identifi ed. The meta-
analysis of the results of these trials 
documented that decision aids improved 
many aspects of decision quality. Subjects 
randomized to patient decision aids rather 
than usual care had greater knowledge, 
had lower decisional confl ict relating 
to feeling informed and feeling unclear 
about personal values, were less likely to 
be passive in decision making, and were 
less likely to remain undecided about a 
management option. Decision aids also 
reduced rates of elective surgery and PSA 
screening by about 20%(11). 
The Prostate-Specifi c Antigen (PSA) 
Screening Decision
The PSA test was introduced into 
clinical medicine in the United States 
in the late 1980’s, initially as a tool for 
managing men with a known prostate 
cancer diagnosis. However, clinicians 
quickly began using the PSA test for 
early detection of prostate cancer among 
asymptomatic men. Because of the large 
reservoir of prostate cancers among older 
men never destined to present clinically, 
this strategy resulted in almost a doubling 
of the incidence of prostate cancer in the 
United States over just fi ve years between 
1987, when the PSA test was introduced, 
and 1992 (Figure 1). By 2005, about half of 
American men age 50-79 reporting having 
had a PSA test within the last two years(12), 
despite no randomized trials proving that 
PSA screening does more good than harm. 
At the individual level, widespread PSA 
screening in the United States has resulted 
in the predicted lifetime risk of a prostate 
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cancer diagnosis increasing from about 9% 
in 1985(13), before PSA screening, to about 
16% based on incidence data from 2005-
2007(14).
Since the incidence peak in the United 
States in 1992, population-based prostate 
cancer mortality has dropped by about 
25% through 2005 (Figure 1). Screening 
advocates have considered this trend 
prima facie evidence that PSA screening 
is effective at reducing prostate cancer 
mortality, and is therefore worth the price 
in terms of the much higher risk that men 
will have to face a diagnosis of prostate 
cancer over their lifetimes, with all the 
attendant anxiety and treatment side effects 
screening engenders. 
However, recent randomized trials 
of PSA screening have not resoundingly 
proved that the benefi ts of PSA screening 
so far outweigh its harms that it can be 
considered proven effective care, to be 
routinely implemented in clinical practice 
and public health. To some extent, this at 
best modest effectiveness is in part related 
to the poor sensitivity and specifi city of the 
test. While a relatively high false positive 
rate has been appreciated for many years, 
an appreciable false negative rate, even for 
high-grade cancers, has been appreciated 
only recently(15). A large trial of PSA 
screening in the United States randomized 
about 77,000 men to receive either annual 
PSA screening (with digital rectal exams) 
or “usual care”(2). After a median follow-up 
of 11.5 years, the rate of a prostate cancer 
diagnosis was 22% higher with screening, 
but prostate-cancer specifi c mortality was 
not signifi cantly reduced; in fact, the trend 
suggested more prostate cancer deaths with 
screening. Major concerns about this trial 
have included prescreening of a substantial 
proportion of the study population with 
PSA tests before trial entry, contamination 
of the control group with about half of 
control men receiving PSA tests, and an 
insuffi cient follow-up duration. 
An even larger trial conducted in 
multiple European countries randomized 
a core group of about 162,000 men age 
55-69 to more infrequent PSA screening 
(without digital rectal exams) than in the 
Figure 1. Prostate Cancer Mortality and Incidence in the U.S., 1987-2007,
adjusted for age(14)
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US trial, usually every four years, versus 
usual care(3). In the European trial, after 
a median follow-up of nine years, the 
cumulative risk of a prostate cancer 
diagnosis increased about 70% with 
screening, from 4.8% in the control group 
to 8.2% in the screened group. However, 
the death rate from prostate cancer was 
20% lower, albeit with an absolute risk 
difference of about 7 fewer deaths per 
10,000 men screened. In a subsequent 
analysis, the investigators estimated that 
with correction for contamination and 
dilution of the control and screening 
groups, respectively, the “true” benefi t of 
consistent PSA screening might be closer 
to a 30% reduction in prostate cancer 
mortality(16).
A recent meta-analysis of these trials 
and several smaller ones estimated that 
across the trials screening resulted in 
a 46% higher probability of a prostate 
cancer diagnosis with screening, with no 
signifi cant effect on prostate cancer or 
overall mortality, although the lower limits 
of the 95% confi dence intervals were still 
consistent with a 29% and 3% reduction 
in these outcomes, respectively(17). 
Given the quality of the evidence 
currently available, there is considerable 
uncertainty about the most effective and 
effi cient strategy for using the PSA test 
for early detection of prostate cancer. 
Issues such as the frequency of testing, 
the ideal starting and stopping ages, the 
right threshold to consider a PSA level 
suspicious enough to warrant a biopsy, 
and whether PSA testing and digital rectal 
examinations should be combined, all 
engender heated debate. For example, one 
recent publication suggested an optimal 
strategy might be a single PSA test at age 
60, with no further testing for men with 
low values(18).
If there were no side effects from 
the diagnosis and treatment of prostate 
cancer, there would be much less 
controversy about screening. However, 
prostate biopsies done in response to an 
elevated PSA level can be complicated by 
bleeding or infection. More importantly, 
men who have prostate cancer diagnosed 
by screening usually consider treatment 
with some form of surgery or radiation 
(see subsequent section). Surgery for 
prostate cancer has a small but fi nite risk 
of operative mortality, and radiation has 
a small risk of rectal injury resulting in 
gastrointestinal side effects. Both treatments 
carry a substantial risk of problems with 
continence and erectile function(19).
Because of the uncertain benefi ts and 
known risk of prostate cancer screening, 
national clinical practice guidelines in the 
United States began recommending a shared 
decision making approach to PSA screening 
as early as 1997, when the American 
College of Physicians’ clinical guideline 
recommended, “Rather than screen all men 
for prostate cancer as a matter of routine, 
physicians should describe the potential 
benefi ts and known harms of screening, 
diagnosis, and treatment; listen to the 
patients’ concerns; and then individual the 
decision to screen”(20). Though many had 
hoped the US and European randomized 
trials would show that the benefi ts of PSA 
screening defi nitively outweighed the harms 
or vice versa, the results to date continue 
to suggest a close call, and considering 
patient preferences therefore remains 
critical for optimal decision making. As a 
result, new guidelines recently released 
by the American Cancer Society (ACS) 
after publication of the US and European 
screening trials emphasize shared decision 
making: “The ACS recommends that 
asymptomatic men who have at least a 10-
year life expectancy have an opportunity 
to make an informed decision with their 
health care provider about screening 
for prostate cancer after they receive 
information about the uncertainties, risks, 
and potential benefi ts associated with 
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prostate cancer screening…Patient decision 
aids are helpful in preparing men to make a 
decision whether to be tested”(21).
Patient Decision Aids for PSA Screening
The key decision for older men reaching 
the age of 50, or age 40-45 if they have 
risk factors such as African ancestry or a 
fi rst degree relative with prostate cancer, 
is whether to undergo periodic PSA testing 
for the early detection of prostate cancer. 
Although the evidence regarding the 
effectiveness of digital rectal examinations 
for prostate cancer screening is also 
problematic, this preventive maneuver 
has in general received less attention in 
medical decision-making. Interestingly, the 
European trial of prostate cancer screening, 
which arguably provides the best evidence 
for the effectiveness of early detection, did 
not include digital rectal exams. 
The Ottawa Hospital Research Institute 
(OHRI) A to Z Inventory of Decision Aids 
web site lists six currently available patient 
decision aids on PSA screening; from the 
Centers for Disease Control (including a 
general Decision Guide and a Decision 
Guide for African Americans), Health 
Dialog, Healthwise, the Mayo Clinic, and 
the University of Cardiff(22). These decision 
aids generally rated fairly high on the 
IPDAS criteria, which are also available on 
the OHRI web site.
Volk et al. performed a systematic 
review and meta-analysis of trials of 
PSA decisions aids, with the search for 
publications conducted through the 
end of 2006(23). They identifi ed 18 trials 
involving 6,221 participants, all using 
patient decision aids in the English 
language. Consistent with the results of 
the Cochrane review for decision aids in 
general, they found decision aids improved 
subjects’ knowledge about PSA testing 
and made patients more confi dent about 
their decisions. They also found subjects 
exposed to decision aids as part of routine 
clinical care (but not subjects specifi cally 
seeking screening) were signifi cantly less 
interested in PSA testing, with a relative 
risk of 0.88 (95% confi dence interval 0.81, 
0.97) in nine trials reporting that outcome. 
A Cochrane review conducted at about the 
same time focused on fi ve trials of decision 
aids versus usual care, also found PSA 
screening interest signifi cantly reduced 
with decision aids, with a relative risk of 
0.80 (95% confi dence interval 0.7, 1.0)(11). 
Thus, it appears that well informed patients 
indeed become somewhat less interested 
in PSA screening. A paradox is that as of 
the time of this publication, there were no 
published high quality randomized trials 
of PSA screening, yet PSA screening was 
widespread, at least in the United States. 
And despite 18 trials showing patient 
decision aids improved decision quality for 
PSA screening, their use was, and remains, 
rare in clinical practice.
Several more recent randomized trials 
of decision aids for PSA screening deserve 
mention. Krist et al. randomized 496 men 
in a single family medical practice to a 
paper-based decision aid or an internet-
based decision aid of their own design and 
compared outcomes to control subjects(24). 
As in previous trials, knowledge and 
involvement in decision-making were 
increased, and PSA testing was reduced 
with both decision aids, with no important 
differences between the two decision aid 
formats. 
Frosh et al. randomized 611 men from a 
Health Appraisal Clinic at Kaiser Permanate 
in a 2x2 factorial design to three variants 
of internet-based decision aids compared 
to referral to public web sites on prostate 
cancer screening maintained by the 
American Cancer Society and the Centers 
for Disease Control and Prevention(25). The 
more specifi cally designed internet decision 
aids signifi cantly improved decision quality 
and reduced uptake of PSA tests more 
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effectively than referral to the public web 
sites.
Another trial by Allen et al. used the 
novel approach of delivering a prostate 
cancer screening decision aid to men age 
45 and older in work sites(26). In this cluster 
randomized trial involving 625 subjects, 
decision quality was also improved, despite 
relatively low uptake, about 30%, among 
men randomized to the intervention.
Rubel et al. conducted a randomized 
trial of the paper-based decision aid for 
prostate cancer screening from the Centers 
for Disease Control and Prevention 
listed in the OHRI inventory mentioned 
previously(27). Again, consistent with 
earlier studies, the decision aid increased 
knowledge and improved other aspects of 
decision quality.
Finally, another web-based trial of the 
effect of the Prosdex decision aid from 
the University of Cardiff, also listed in 
the OHRI inventory, was published by 
Evans et al.(28) . This trial randomized men 
to an internet-based or paper version of 
Prosdex, or a control group. Once again, 
men randomized to the decision aids had 
improved knowledge, lower decisional 
confl ict, and no higher anxiety levels than 
controls. Interestingly, particularly because 
of the paucity of research on internet-based 
versus more traditional paper- and video-
based decision aids, men randomized to 
the internet version had lower PSA testing 
uptake than men randomized to the paper-
based decision aid group and the control 
group, although uptake was very low 
overall, probably refl ecting the low level 
of PSA screening in Wales, where the study 
was conducted.
The Clinically Localized Prostate Cancer 
Treatment Decision
Treatment options for prostate 
cancer depend on the stage of disease. 
For prostate cancers that are judged 
likely to be confi ned to the prostate 
gland, attempted curative treatments 
include radical prostatectomy (open or 
laparopscopic surgery, often robotic-
assisted) and radiation therapy (conformal 
external beam radiotherapy, intensity-
modulated radiotherapy, brachytherapy, 
proton beam therapy, and robotic 
radiosurgery). Men may also pursue 
some form of watchful waiting (including 
delayed attempted curative treatment for 
cancer progression, also called “active 
surveillance”)(29). For prostate cancers 
with a higher risk of extracapsular disease, 
neoadjuvant androgen deprivation therapy 
may be added, particularly to radiation 
therapy(30). Androgen deprivation therapy 
is the mainstay of treatment for metastatic 
prostate cancer. Another common 
situation where androgen deprivation is 
considered is a rising PSA after attempted 
curative treatment, evidence of residual or 
recurrent disease(31).
In areas where PSA screening is 
widespread, particularly in the U.S., 
the great majority of men present with 
clinically localized disease. Up to 25% 
of men who receive attempted curative 
therapy will have a rising PSA as some 
point after treatment(32). For such men, few 
randomized trials are available to guide 
decision making(33). In a single Scandinavian 
randomized trial comparing radical 
prostatectomy to watchful waiting for men 
with clinically localized cancer, surgery 
signifi cantly decreased the probability 
of dying of prostate cancer from about 
18% to 12.5% over a median of about 
11 years of follow, with a similar though 
nonsignifi cant 5% absolute reduction in 
overall mortality(1,34). This mortality benefi t 
appeared confi ned to men younger than 
age 65 at diagnosis (interestingly, about 
one-third of men who undergo radical 
prostatectomy in the United states are 
65 or older(35)), and does not seem to 
increase further after ten years of follow-
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up. Moreover, few men in this study were 
diagnosed through PSA screening. The 
PIVOT trial being conducted in the United 
States and initiated in 1994 has a similar 
design but includes men largely diagnosed 
through PSA screening(33). Results from 
PIVOT are expected in 2011.
Given the paucity of randomized trials 
and the plethora of treatment options, any 
judgments about comparative effectiveness 
must necessarily focus on nonexperimental 
studies. The Institute for Clinical and 
Economic Review at Massachusetts 
General Hospital has summarized these 
data in a series of reports (see http://www.
icer-review.org/).
Patient Decision Aids for Prostate Cancer 
Treatment
Decisions about prostate cancer 
treatment, particularly for men with 
clinically localized disease, can be 
bewildering, given the many options, 
the weak evidence on comparative 
effectiveness, and strong fi nancial 
incentives for manufacturers, clinicians 
and hospitals to promote particular 
therapies(29). Shared decision making has 
been widely endorsed for prostate cancer 
treatment decisions(30,36).
The OHRI Inventory lists fi ve decision 
aids for prostate cancer treatment, four 
addressing attempted curative treatment 
for clinically localized prostate cancer 
from Health Dialog, Healthwise, the Mayo 
Clinic, and the National Cancer Institute, 
and another from Health Dialog addressing 
the timing of androgen deprivation for a 
rising PSA after surgery or radiation therapy. 
Again, these decision aids generally 
perform well against the IPDAS criteria.
Lin et al. performed a systematic review 
of studies (not just trials) of decision aids for 
prostate cancer treatment with the search 
covering through early 2009(37). Thirteen 
studies including just three randomized 
trials were identifi ed. Although the 
evidence base is weaker for the effect of 
decision aids on prostate cancer treatment 
compared with screening decisions, the 
authors concluded that decision aids 
improve knowledge, encourage more 
active involvement in decision making, and 
decrease levels of anxiety ands stress. The 
effect on treatment choice was less clear, 
although in European studies, fewer men 
chose radical prostatectomy compared to 
historical controls.
Conclusions
In summary, randomized trials of 
different patient decision aids addressing 
prostate cancer screening in different 
study settings have consistently shown 
improvements in decision quality and, 
taken together, lower interest in and 
uptake of PSA testing when patients 
are well informed. In addition, use of 
patient decision aids for prostate cancer 
screening may actually reduce concerns 
about medical-legal liability if men do not 
undergo PSA screening(38). Nevertheless, 
the uptake of patient decision aids 
themselves to help men make shared 
decisions about PSA screening, as 
recommended by many clinical practice 
guidelines, is low. Given the evidence of 
effectiveness, research is urgently needed 
addressing how to routinely implement 
decision aids for PSA screening, as well as 
other fateful decisions, in routine clinical 
practice. Legare et al. have conducted 
a systematic review of trials addressing 
interventions for improving the adoption 
of shared decision making by healthcare 
professionals(39). Because so few trials were 
identifi ed, the authors concluded, “The 
results of this Cochrane review do not 
allow us to draw fi rm conclusions about 
the most effective types of interventions 
for increasing healthcare professionals use 
of SDM.”
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Unlike the case for shared decision 
making assisted by decision aids for the 
PSA screening decision, more research 
is needed on the effect of decision aids 
on prostate cancer treatment decisions. 
This research should parallel comparative 
effectiveness research for prostate cancer 
treatments themselves, which has been 
listed as a top priority by a recent report 
from the U.S. Institute of Medicine on 
comparative effectiveness research(40). 
However, given the strong evidence for 
patient decision aids in general, and the 
results of the research available to date, it 
is likely further studies will show similar 
salutary effects on decision quality with 
the use of decision aids for prostate cancer 
treatment.
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